Illumina, Inc. (NASDAQ:ILMN) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS
Illumina, Inc. (NASDAQ:ILMN) announced its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.14, Briefing.com reports. The business had revenue of $662 million for the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $0.86 earnings per share. Illumina updated its FY17 guidance to $3.60-3.70 EPS.
Illumina (NASDAQ:ILMN) traded down 0.98% during mid-day trading on Friday, reaching $189.32. The company’s stock had a trading volume of 882,072 shares. The firm’s 50 day moving average is $181.43 and its 200-day moving average is $174.88. The company has a market cap of $27.64 billion, a PE ratio of 37.99 and a beta of 0.83. Illumina has a 12-month low of $119.37 and a 12-month high of $199.95.
Several brokerages have issued reports on ILMN. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Vetr cut Illumina from a “strong-buy” rating to a “hold” rating and set a $202.18 target price on the stock. in a research report on Wednesday, August 2nd. Barclays PLC reissued an “equal weight” rating and issued a $150.00 target price on shares of Illumina in a research report on Wednesday, August 9th. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research report on Monday, August 7th. Finally, Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and raised their target price for the stock from $170.00 to $215.00 in a research report on Monday, August 7th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $177.01.
TRADEMARK VIOLATION WARNING: “Illumina, Inc. (NASDAQ:ILMN) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/19/illumina-inc-nasdaqilmn-issues-quarterly-earnings-results-beats-estimates-by-0-13-eps-updated-updated.html.
In other news, SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $197.00, for a total value of $316,973.00. Following the transaction, the senior vice president now owns 9,037 shares in the company, valued at $1,780,289. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michel Bouchard sold 246 shares of the firm’s stock in a transaction that occurred on Thursday, June 8th. The shares were sold at an average price of $178.91, for a total value of $44,011.86. Following the completion of the transaction, the insider now owns 19,139 shares in the company, valued at approximately $3,424,158.49. The disclosure for this sale can be found here. In the last 90 days, insiders sold 154,010 shares of company stock worth $27,840,615. Company insiders own 1.60% of the company’s stock.
Several large investors have recently bought and sold shares of ILMN. RMB Capital Management LLC bought a new stake in Illumina during the fourth quarter valued at approximately $219,000. Kentucky Retirement Systems bought a new stake in Illumina during the fourth quarter valued at approximately $1,365,000. Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Illumina during the fourth quarter valued at approximately $609,000. Private Asset Management Inc. boosted its stake in Illumina by 10.5% in the first quarter. Private Asset Management Inc. now owns 8,142 shares of the life sciences company’s stock valued at $1,389,000 after buying an additional 775 shares in the last quarter. Finally, Chevy Chase Trust Holdings Inc. boosted its stake in Illumina by 33.0% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 346,451 shares of the life sciences company’s stock valued at $59,114,000 after buying an additional 85,922 shares in the last quarter. 93.91% of the stock is owned by hedge funds and other institutional investors.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.